Modelling and simulation (M&S) has grown to become a reliable approach to better understand and optimize key decisions related to safety, efficacy, dosing, and special target populations. As both computing power and our understanding of human systems biology improve, the increased use of M&S motivates regulators to consider this new type of digital evidence to support medical device and medicinal drug product development and allow new approaches in clinical trials, in view of increasing the probability of success, reduce costs and accelerate time to patients.
Published on: Jan 24, 2020
Download the full publication now
Fill in the form to download the content
publication by
Cécile F. Rousseau, PhD
Senior Director, Nonclinical
With 10+ years in nonclinical and translational research and histotechnology, Dr. Cécile F. Rousseau has considerable expertise in medical devices,…
View profile
Emmanuelle M. Voisin, PhD
Founder and CEO
Dr. Emmanuelle Voisin founded Voisin Consulting Life Sciences (VCLS) in 1997. The firm has become a leading advisor to Biotech,…
View profile
David A duVerle
Chief Scientific Officer at Novadiscovery
Marc Buyse
Chief Scientific Officer at IDDI and CluePoints
François-Henri Boissel
CEO Novadiscovery
All our resources 
